Shire To Acquire Rare-Disease Company ViroPharma - - BioPharm International

ADVERTISEMENT

Shire To Acquire Rare-Disease Company ViroPharma


Shire has entered into a merger agreement to acquire all the outstanding shares of the rare disease company ViroPharma for approximately $4.2 billion, Shire announced in a press release. The acquisition fits with Shire’s strategy to expand its rare-disease portfolio and adds a growing commercial product.

ViroPharma’s commercial product Cinryze (C1 esterase inhibitor [human]) is for the prophylactic treatment of hereditary angioedema (HAE). The product complements Shire’s Firazyr (icatibant injection). Cinryze was approved with orphan drug designation in October 2008 and has grown rapidly since its launch in 2009.

“Shire is uniquely positioned to drive the continued success of Cinryze for the benefit of patients through our knowledge of the rare disease space, our international infrastructure, and our biologics manufacturing expertise,” said Shire CEO, Flemming Ornskov, MD, in the press release.

Source: Shire

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pfizer to Acquire Vaccines from Baxter
July 30, 2014
GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
Author Guidelines

Click here